Breast cancer cells expressing NQO1 shRNAs are not further sensitized to IFNγ and phenformin co-treatment, suggesting that NQO1 is an essential target gene that confers the antitumorigenic effects of phenformin (Fig. 6g). This evidence concerns the gene NQO1 and breast carcinoma.